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• Plasma is also called the fourth state of matter
• Ionized gas composed of reactive species, electrical and excited particles, among other properties
• Cold atmospheric plasmas (CAP) recently came into the attention of medical society 
• They are produced at a temperature below 40.°C → their use does not cause thermal damage
• Non-inflammatory selective ablative effects in tumor cells
• Effects result from interactions between plasma components with specific structural cell elements and cell 
functionalities – oxidative stress response, mitochondrial function, cell cycle regulation and cell death pathways
• Plasma therapy is still a developing field, but it seems to be effective against a wide range of tumors
• Melanoma, Glioblastoma, Breast, colon, lung and cervix cancer
• Knowledge of CAP effect on urological cancers is not yet well stablished
• Goal: This work aims to evaluate cytotoxicity of CAP in prostate and urinary bladder cancer cell lines
• Our group developed an electronic device capable of generating high output voltage that can ionize a 
significant fraction of air particles producing cold atmospheric plasma (CAP)
• Cell lines - plated in a concentration of 50.000-100.000 cells/mL in 200pL of cell culture medium
• Prostate adenocarcinoma - LNCaP and PC3
• Urinary bladder carcinoma - HT1376
• Phenotypically normal human fibroblasts cell line - HFF-1
• The device was designed to expose cell cultures seeded in multiwell plates to short periods of CAP
• Range from 15 to 120 seconds
• Metabolic activity (MA) and protein content (P) were assessed with colorimetric assays MTT and SRB
• CAP was able to reduce the MA of all 3 cancer cell lines by more than 80%.
• PC was also greatly reduced in LNCaP and HT1376 lines, but in PC3 remained almost intact
• This could be due to different cell functions derangement or due to activation of different cell death pathways
• CAP has shown a great anti-tumor effect 
• It may offer a selective anti-tumor therapy capable of providing tumors ablation after brief exposures → in a range of seconds or minutes
• Spares normal adjacent tissues. 
• In the future, with more studies, it could be used to treat superficial cancers, like bladder cancer, or to obtain an oncological sterilization of the surgical margins, like after a radical prostatectomy
In figure MTT and SRB assay results 24 h after plasma therapy application in different human cell lines: prostate adenocarcinoma (PC3
andLNCap), urinary bladder carcinoma (HT1376) and fibroblasts (HFF1) at distinct times: 15, 30, 60, 90 and 120 seconds (s)
Results are expressed as percentage of protein content normalized to control
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